Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00055809 · ClinicalTrials.gov registry record · Phase 2

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

A Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
44
Enrollment target
1
Study location

NCT00055809 is a Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, below the 96-participant average among 4 other Metastatic Gastrointestinal Carcinoid Tumor trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00055809, a Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells

Conditions Studied

Metastatic Gastrointestinal Carcinoid Tumor Recurrent Gastrointestinal Carcinoid Tumor Regional Gastrointestinal Carcinoid Tumor

Interventions

  • OTHER laboratory biomarker analysis
  • BIOLOGICAL bevacizumab
  • BIOLOGICAL PEG-interferon alfa-2b

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2003-01
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00055809

The ClinicalTrials.gov registry entry for NCT00055809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 4 other Metastatic Gastrointestinal Carcinoid Tumor trials with a reported enrollment target (54% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Gastrointestinal Carcinoid Tumor appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00055809 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00055809 about?

NCT00055809 is a clinical study titled "Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors". This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells...

What is the current status of trial NCT00055809?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2003-01.

What conditions does trial NCT00055809 study?

This clinical trial studies the following conditions: Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor.

What interventions are being tested in trial NCT00055809?

The interventions under investigation include: laboratory biomarker analysis (OTHER), bevacizumab (BIOLOGICAL), PEG-interferon alfa-2b (BIOLOGICAL).

Who is sponsoring clinical trial NCT00055809?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00055809 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Gastrointestinal Carcinoid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Gastrointestinal Carcinoid Tumor

All registered trials for this condition

Recurrent Gastrointestinal Carcinoid Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.